Total Payments
$1.4M
2024 Payments
$148,238
Companies
44
Transactions
2,264
Medicare Patients
8,345
Medicare Billing
$4.1M
Payment Breakdown by Category
Other$1.0M (71.8%)
Consulting$205,614 (14.5%)
Travel$138,435 (9.8%)
Food & Beverage$54,584 (3.9%)
Education$124.32 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.0M | 498 | 71.6% |
| Consulting Fee | $205,614 | 106 | 14.5% |
| Travel and Lodging | $138,435 | 411 | 9.8% |
| Food and Beverage | $54,584 | 1,237 | 3.9% |
| Honoraria | $1,950 | 2 | 0.1% |
| Grant | $250.00 | 1 | 0.0% |
| Education | $124.32 | 9 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $390,443 | 540 | $0 (2024) |
| GlaxoSmithKline, LLC. | $339,229 | 483 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $165,494 | 286 | $0 (2024) |
| GENZYME CORPORATION | $104,695 | 105 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $97,188 | 140 | $0 (2024) |
| Genentech USA, Inc. | $87,409 | 141 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $86,622 | 176 | $0 (2022) |
| Mylan Specialty L.P. | $46,740 | 81 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $39,272 | 85 | $0 (2020) |
| Amgen Inc. | $20,484 | 44 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $148,238 | 201 | AstraZeneca Pharmaceuticals LP ($70,947) |
| 2023 | $335,042 | 373 | GlaxoSmithKline, LLC. ($114,828) |
| 2022 | $149,570 | 157 | AstraZeneca Pharmaceuticals LP ($56,361) |
| 2021 | $145,788 | 211 | AstraZeneca Pharmaceuticals LP ($54,013) |
| 2020 | $113,207 | 219 | GlaxoSmithKline, LLC. ($34,573) |
| 2019 | $297,249 | 522 | GlaxoSmithKline, LLC. ($101,507) |
| 2018 | $142,596 | 356 | Boehringer Ingelheim Pharmaceuticals, Inc. ($56,374) |
| 2017 | $82,263 | 225 | Genentech USA, Inc. ($19,462) |
All Payment Transactions
2,264 individual payment records from CMS Open Payments — Page 1 of 91
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,350.00 | General |
| Category: RESPIRATORY | ||||||
| 12/19/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,200.00 | General |
| Category: Respiratory | ||||||
| 12/18/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,202.00 | General |
| Category: Immunology | ||||||
| 12/18/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Travel and Lodging | In-kind items and services | $1,081.40 | General |
| Category: Immunology | ||||||
| 12/18/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Food and Beverage | In-kind items and services | $108.24 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $23.53 | General |
| Category: Inflammation | ||||||
| 12/11/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $8.66 | General |
| Category: Inflammation | ||||||
| 12/10/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $24.26 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $43.80 | General |
| 12/05/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,202.00 | General |
| Category: Immunology | ||||||
| 12/05/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Travel and Lodging | Cash or cash equivalent | $80.40 | General |
| Category: Immunology | ||||||
| 12/05/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Food and Beverage | In-kind items and services | $65.97 | General |
| Category: Immunology | ||||||
| 12/05/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $21.23 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $10.66 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Respiratory | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $32.58 | General |
| Category: Respiratory | ||||||
| 11/27/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Consulting Fee | Cash or cash equivalent | $537.00 | General |
| Category: Respiratory | ||||||
| 11/26/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,530.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/26/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,050.00 | General |
| Category: Respiratory | ||||||
| 11/26/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: Inflammation | ||||||
| 11/21/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,366.00 | General |
| Category: Immunology | ||||||
| 11/21/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Immunology | ||||||
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $13.71 | General |
| Category: Respiratory | ||||||
| 11/20/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $68.88 | General |
| Category: RESPIRATORY | ||||||
| 11/19/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $15.37 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 2,283 | 46,067 | $3.3M | $932,762 |
| 2022 | 16 | 2,160 | 21,078 | $3.0M | $869,355 |
| 2021 | 17 | 1,608 | 19,488 | $2.9M | $889,624 |
| 2020 | 20 | 2,294 | 29,772 | $4.4M | $1.4M |
Total Patients
8,345
Total Services
116,405
Medicare Billing
$4.1M
Procedure Codes
76
All Medicare Procedures & Services
76 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2182 | Injection, mepolizumab, 1 mg | Office | 2023 | 29 | 17,500 | $881,401 | $261,010 | 29.6% |
| J0517 | Injection, benralizumab, 1 mg | Office | 2023 | 30 | 2,850 | $736,320 | $234,780 | 31.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 517 | 1,111 | $512,171 | $153,952 | 30.1% |
| J2356 | Injection, tezepelumab-ekko, 1 mg | Office | 2023 | 20 | 22,470 | $449,821 | $153,509 | 34.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 174 | 174 | $114,144 | $28,910 | 25.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 238 | 290 | $99,470 | $26,910 | 27.1% |
| 95806 | Sleep study including heart rate, breathing, airflow, and effort | Office | 2023 | 268 | 275 | $222,750 | $20,312 | 9.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 48 | 91 | $31,395 | $8,830 | 28.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 25 | 50 | $45,100 | $8,583 | 19.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 66 | 66 | $34,386 | $7,215 | 21.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 30 | 31 | $20,553 | $4,385 | 21.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 77 | 380 | $28,500 | $4,288 | 15.0% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 185 | 189 | $24,546 | $4,041 | 16.5% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 193 | 197 | $23,909 | $3,891 | 16.3% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2023 | 37 | 40 | $21,480 | $3,764 | 17.5% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 191 | 195 | $22,888 | $3,151 | 13.8% |
| 31624 | Irrigation and suction of lung airways to obtain cells using an endoscope | Facility | 2023 | 19 | 19 | $24,130 | $1,929 | 8.0% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 55 | 58 | $8,178 | $1,578 | 19.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 20 | 20 | $4,680 | $1,195 | 25.5% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Facility | 2023 | 19 | 19 | $4,085 | $178.56 | 4.4% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2023 | 14 | 14 | $728.00 | $136.22 | 18.7% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2023 | 14 | 14 | $686.00 | $116.48 | 17.0% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 14 | 14 | $504.00 | $100.66 | 20.0% |
| J0517 | Injection, benralizumab, 1 mg | Office | 2022 | 30 | 2,850 | $950,400 | $317,125 | 33.4% |
| J2182 | Injection, mepolizumab, 1 mg | Office | 2022 | 26 | 15,201 | $956,274 | $280,751 | 29.4% |
About Dr. Shyamsunder Subramanian, MD
Dr. Shyamsunder Subramanian, MD is a Critical Care Medicine healthcare provider based in Tracy, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/16/2005. The National Provider Identifier (NPI) number assigned to this provider is 1871588731.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Shyamsunder Subramanian, MD has received a total of $1.4M in payments from pharmaceutical and medical device companies, with $148,238 received in 2024. These payments were reported across 2,264 transactions from 44 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.0M).
As a Medicare-enrolled provider, Subramanian has provided services to 8,345 Medicare beneficiaries, totaling 116,405 services with total Medicare billing of $4.1M. Data is available for 4 years (2020–2023), covering 76 distinct procedure/service records.
Ad
Practice Information
- Specialty Critical Care Medicine
- Other Specialties Pulmonary Disease
- Location Tracy, CA
- Active Since 09/16/2005
- Last Updated 12/15/2015
- Taxonomy Code 207RC0200X
- Entity Type Individual
- NPI Number 1871588731
Products in Payments
- DUPIXENT (Biological) $180,789
- NUCALA (Biological) $170,827
- TEZSPIRE (Biological) $119,446
- TRELEGY ELLIPTA (Drug) $75,480
- FASENRA (Drug) $75,321
- BREZTRI (Drug) $73,377
- FASENRA (Biological) $60,341
- OFEV (Drug) $58,619
- Esbriet (Biological) $51,641
- CINQAIR (Biological) $46,207
- AREXVY (Drug) $39,963
- Yupelri (Drug) $38,622
- AIRSUPRA (Drug) $36,630
- Xolair (Biological) $23,525
- ProAir Digihaler (Drug) $18,114
- LONHALA MAGNAIR (Drug) $17,405
- BEVESPI AEROSPHERE (Drug) $14,225
- DUPIXENT (Drug) $13,516
- CINQAIR (Drug) $11,792
- STIOLTO RESPIMAT (Drug) $10,955
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.